PRAXIS PRECISION MEDICINES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.31M, a 45.55% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $17.11M, a 94.76% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.45M, a 40.10% decline year-over-year.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.77M, a 32.19% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $33.94M, a 17.94% decline from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $41.36M, a 66.39% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $24.86M.
- PRAXIS PRECISION MEDICINES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $5.21M, a 680.09% increase from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.31M 10-Q · filed 2026-08-06 | $28.42M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $17.11M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $33.94M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $7.45M 10-Q · filed 2025-11-05 | $15.22M derived: sum of 2 quarters · filed 2026-08-06 | $24.00M derived: sum of 3 quarters · filed 2026-08-06 | $32.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.77M 10-Q · filed 2026-08-06 | $16.56M derived: sum of 2 quarters · filed 2026-08-06 | $25.13M derived: sum of 3 quarters · filed 2026-08-06 | $37.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.79M 10-Q · filed 2026-08-06 | $17.36M derived: sum of 2 quarters · filed 2026-08-06 | $29.79M derived: sum of 3 quarters · filed 2026-08-06 | $35.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $8.57M 10-K · filed 2025-02-28 | $21.01M derived: sum of 2 quarters · filed 2025-11-05 | $26.89M derived: sum of 3 quarters · filed 2025-11-05 | $41.36M 10-K · filed 2026-02-19 |
| 2024-09-30 | $12.43M 10-Q · filed 2025-11-05 | $18.31M derived: sum of 2 quarters · filed 2025-11-05 | $32.78M derived: sum of 3 quarters · filed 2025-11-05 | $38.51M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $5.88M 10-Q · filed 2025-11-05 | $20.35M derived: sum of 2 quarters · filed 2025-11-05 | $26.08M derived: sum of 3 quarters · filed 2025-11-05 | $31.84M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-03-31 | $14.47M 10-Q · filed 2025-11-05 | $20.20M derived: sum of 2 quarters · filed 2025-11-05 | $25.96M derived: sum of 3 quarters · filed 2025-11-05 | $31.74M derived: sum of 4 quarters · filed 2025-11-05 |
| 2023-12-31 | $5.73M 10-K · filed 2025-02-28 | $11.49M derived: sum of 2 quarters · filed 2025-02-28 | $17.26M derived: sum of 3 quarters · filed 2025-02-28 | $24.86M 10-K · filed 2026-02-19 |
| 2023-09-30 | $5.76M 10-K · filed 2025-02-28 | $11.54M derived: sum of 2 quarters · filed 2025-02-28 | $19.13M derived: sum of 3 quarters · filed 2025-02-28 | $25.50M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $5.78M 10-K · filed 2025-02-28 | $13.37M derived: sum of 2 quarters · filed 2025-02-28 | $19.73M derived: sum of 3 quarters · filed 2025-02-28 | $26.46M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $7.59M 10-K · filed 2025-02-28 | $13.96M derived: sum of 2 quarters · filed 2025-02-28 | $20.69M derived: sum of 3 quarters · filed 2025-02-28 | $28.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $6.37M 10-K · filed 2024-03-05 | $13.10M derived: sum of 2 quarters · filed 2024-03-05 | $20.71M derived: sum of 3 quarters · filed 2024-03-05 | $28.59M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-09-30 | $6.73M 10-K · filed 2024-03-05 | $14.34M derived: sum of 2 quarters · filed 2024-03-05 | $22.23M derived: sum of 3 quarters · filed 2024-03-05 | $28.33M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $7.61M 10-K · filed 2024-03-05 | $15.50M derived: sum of 2 quarters · filed 2024-03-05 | $21.60M derived: sum of 3 quarters · filed 2024-03-05 | $28.12M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $7.89M 10-K · filed 2024-03-05 | $13.99M derived: sum of 2 quarters · filed 2024-03-05 | $20.51M derived: sum of 3 quarters · filed 2024-03-05 | $25.91M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $6.11M 10-K · filed 2023-02-07 | $12.63M derived: sum of 2 quarters · filed 2023-02-07 | $18.03M derived: sum of 3 quarters · filed 2023-02-07 | $22.69M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-09-30 | $6.52M 10-K · filed 2023-02-07 | $11.92M derived: sum of 2 quarters · filed 2023-02-07 | $16.59M derived: sum of 3 quarters · filed 2023-02-07 | $20.41M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $5.40M 10-K · filed 2023-02-07 | $10.07M 10-Q · filed 2021-08-16 | $13.89M derived: sum of 3 quarters · filed 2023-02-07 | $14.85M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | $4.67M 10-K · filed 2023-02-07 | $8.49M derived: sum of 2 quarters · filed 2023-02-07 | $9.45M derived: sum of 3 quarters · filed 2023-02-07 | $9.73M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | $3.83M 10-K · filed 2022-02-28 | $4.78M derived: sum of 2 quarters · filed 2022-02-28 | $5.06M derived: sum of 3 quarters · filed 2022-02-28 | $5.21M 10-K · filed 2021-03-17 |
| 2020-09-30 | $953.00K 10-K · filed 2022-02-28 | $1.24M derived: sum of 2 quarters · filed 2022-02-28 | $1.39M 10-Q · filed 2020-11-23 | $1.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $285.00K 10-K · filed 2022-02-28 | $432.00K 10-Q · filed 2021-08-16 | $590.00K derived: sum of 3 quarters · filed 2022-02-28 | $866.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $147.00K 10-K · filed 2022-02-28 | $305.00K derived: sum of 2 quarters · filed 2022-02-28 | $581.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $434.00K derived: sum of 2 quarters · filed 2021-03-17 | $668.00K 10-K · filed 2021-03-17 | |
| 2019-09-30 | $276.00K 10-Q · filed 2020-11-23 | $510.00K 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |